Skip to main content
. 2017 Feb 1;113(3):321–331. doi: 10.1093/cvr/cvx002

Figure 3.

Figure 3

nNOS.eGFP reduces contractility and [Ca2+]i transients in LV myocytes from nNOS−/− mice. (A) Isoproterenol (ISO, 10 nmol/L) increased cell shortening in both nNOS.eGFP and eGFP expressing myocytes (****P < 0.0001 vs. Basal, n = 12–21 cells, four hearts per group; two-way ANOVA). Both basal and ISO-stimulated cell shortening were lower in AdV.nNOS.eGFP transduced myocytes compared with AdV.eGFP controls (**P < 0.01, two-way ANOVA). These differences were lost after incubation with L-NAME (1 mmol/L, n = 10–14 cells, three hearts per group). (B) Representative [Ca2+]i transients obtained in fura-2 loaded, field-stimulated (3 Hz, 35 °C) LV myocytes from nNOS.eGFP- or eGFP-transduced nNOS−/− hearts. ISO (10 nmol/L) increased the amplitude of the [Ca2+]i transients in both groups (****P < 0.0001 vs. Basal, n = 12–23 cells from four hearts; two-way ANOVA); however, the amplitude of the [Ca2+]i transients was significantly lower in nNOS−/− myocytes transduced with AdV.nNOS.eGFP both under basal conditions and in the presence of ISO (*P < 0.05, **P < 0.01 vs. eGFP; two-way ANOVA).